Status: Not yet recruiting
A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis
This study is a multicenter, randomized, prospective trial designed to evaluate the efficacy and safety of pegylated interferon α-2b (Peg-IFN-α2b) combined with nucleos(t)ide analogues (NAs) versus NAs monotherapy in patients with compensated hepatitis B cirrhosis. A total of 30 patients with compensated HBV-related cirrhosis will be enrolled and randomized in a 2:1 ratio to either Experimental Group 1 (n=20) or Experimental Group 2 (n=10). The treatment regimens consist of Peg-IFN-α2b combined with NAs (ETV/TAF/TMF/TDF) or NAs (ETV/TAF/TMF/TDF) monotherapy.
Participants needed: 30
Trial details
Age: 18-60Biological sex: AllType: InterventionalSponsor: Xiamen Humanity HospitalUpdated: Sep 19, 2025Locations: 2
Eligibility criteria
Clinical diagnosis of compensated HBV-related liver cirrhosis (Child-Pugh class... [+4]
Decompensated liver cirrhosis, hepatic failure, or hepatocellular carcinoma; pre... [+5]